A phase I, multicenter, dose-escalation study of MDX-1100 (anti-CXCL10 human monoclonal antibody) in patients with active ulcerative colitis

Trial Profile

A phase I, multicenter, dose-escalation study of MDX-1100 (anti-CXCL10 human monoclonal antibody) in patients with active ulcerative colitis

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2010

At a glance

  • Drugs Eldelumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Medarex
  • Most Recent Events

    • 25 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top